Ascendis Pharma, Inc.
Pharmaceutical & medical device company payment data from CMS Open Payments.
Payment Breakdown by Category
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Unspecified | $11.1M | 3,260 | 82.2% |
| Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | $1.5M | 577 | 10.8% |
| Consulting Fee | $417,251 | 145 | 3.1% |
| Travel and Lodging | $293,413 | 1,100 | 2.2% |
| Food and Beverage | $239,513 | 6,664 | 1.8% |
| Education | $367.36 | 36 | 0.0% |
Payments by Type
Research Studies & Clinical Trials
| Study Name | Total Paid | Doctors | Records |
|---|---|---|---|
| foresiGHt | $2.5M | 0 | 274 |
| New InsiGHts | $1.7M | 0 | 703 |
| enliGHten | $1.6M | 0 | 510 |
| foresiGHt extension | $1.0M | 0 | 136 |
| PaTH Forward | $863,837 | 0 | 179 |
| ApproaCH | $742,970 | 0 | 54 |
| PaTHway TRIAL | $694,652 | 1 | 107 |
| EAP of Palopegteriparatide in Patients With Hypoparathyroidism | $566,781 | 0 | 1,064 |
| SkybriGHt | $552,858 | 1 | 83 |
| SkyPASS | $540,885 | 1 | 81 |
| PaTHway | $204,267 | 0 | 54 |
| Emerald | $117,310 | 0 | 7 |
| IL Believe: A Phase 1/2, Open-label, Dose Escalation and Dose Expansion Study to Investigate the Safety and Tolerability of TransCon IL-2 / Alone or in Combination with Pembrolizumab or Standard of Care Chemotherapy in Participants Aged 18 Years or Older with Locally Advanced or Metastatic Solid Tumor Malignancies | $52,838 | 0 | 7 |
| BelieveIT-201 | $34,710 | 0 | 1 |
Payments by Medical Specialty
Top Paid Doctors — Page 2
| Doctor | Specialty | Location | Total | 2024 |
|---|---|---|---|---|
| Dr. Rodrigo Valderrama, Md, MD | Endocrinology, Diabetes & Metabolism | Birmingham, AL | $21,381 | $0 |
| Dr. Beverly Biller, Md, MD | Internal Medicine | Boston, MA | $20,966 | $0 |
| Edward Lewiecki, M.d, M.D | Internal Medicine | Albuquerque, NM | $20,031 | $0 |
| Paul Saenger, Md, MD | Pediatric Endocrinology | Mineola, NY | $19,098 | $0 |
| Dr. Michael Shanik, M.d, M.D | Endocrinology, Diabetes & Metabolism | Smithtown, NY | $18,585 | $0 |
| Mitchell Geffner, Md, MD | Pediatric Endocrinology | Los Angeles, CA | $18,563 | $0 |
| Ruban Dhaliwal, Md, MD | Endocrinology, Diabetes & Metabolism | Dallas, TX | $18,352 | $0 |
| Hector Granados, Md, MD | Pediatrics | El Paso, TX | $17,510 | $0 |
| Diwakar Davar | Hematology & Oncology | Pittsburgh, PA | $15,635 | $0 |
| Andrew Hoffman, M.d, M.D | Internal Medicine | Stanford, CA | $13,848 | $0 |
| Francis Tintani, M.d, M.D | Student in an Organized Health Care Education/Training Program | Baltimore, MD | $13,515 | $0 |
| Dr. Steven Harris, M.d, M.D | Internal Medicine | San Francisco, CA | $13,445 | $0 |
| Moris Angulo, M.d, M.D | Clinical Genetics (M.D.) | Mineola, NY | $13,327 | $0 |
| Dr. Eric Rush, M.d, M.D | Clinical Genetics (M.D.) | Kansas City, MO | $13,125 | $0 |
| Dr. David Clemmons, Md, MD | Internal Medicine | Chapel Hill, NC | $12,909 | $0 |
| Mary Abuzzahab, Md, MD | Pediatric Endocrinology | Saint Paul, MN | $12,147 | $0 |
| Elvira Gosmanova, Md, MD | Nephrology | Albany, NY | $11,654 | $0 |
| Lisen Liu, Md, MD | Endocrinology, Diabetes & Metabolism | Flushing, NY | $11,607 | $0 |
| Dr. Heidi Shea, M.d, M.D | Endocrinology, Diabetes & Metabolism | Plano, TX | $11,579 | $0 |
| Anastasios Manessis, Md, MD | Endocrinology, Diabetes & Metabolism | New York, NY | $10,347 | $0 |
| Jennifer Kelly, Do, DO | Endocrinology, Diabetes & Metabolism | South Burlington, VT | $10,184 | $0 |
| Andrea Ferenczi, Md, MD | Endocrinology, Diabetes & Metabolism | Scottsdale, AZ | $10,140 | $0 |
| Prof. Terry Davies, Md, Frcp, MD, FRCP | Endocrinology, Diabetes & Metabolism | New York, NY | $9,975 | $0 |
| Dr. Jose Gamez-Godoy, M.d, M.D | Pediatric Endocrinology | Edinburg, TX | $9,895 | $0 |
| Dr. Christian Koch, Md, MD | Endocrinology, Diabetes & Metabolism | Jacksonville, FL | $9,133 | $0 |
About Ascendis Pharma, Inc.
Ascendis Pharma, Inc. has made $13.6M in payments to 2,551 healthcare providers, recorded across 11,782 transactions in the CMS Open Payments database. In 2024, the company paid $4.2M. The top product by payment volume is SKYTROFA ($5.8M).
Payments were distributed across 82 medical specialties. The top specialty by payment amount is Pediatric Endocrinology ($996,259 to 291 doctors).
Payment categories include: Food & Beverage ($239,513), Consulting ($417,251), Research ($11.1M), Travel & Lodging ($293,413).
Ascendis Pharma, Inc. is associated with 3 products in the CMS Open Payments database.